BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardima, Inc. (CRDM) Announces Implementation of One-for-Ten Reverse Stock Split


5/11/2010 9:34:51 AM

FREMONT, Calif.--(BUSINESS WIRE)--Cardima, Inc., a medical device company focused on the treatment of atrial fibrillation and manufacturer of the Cardima Surgical Ablation System, announced today that its common stock will commence trading under the new ticker symbol, “CADMD” following the implementation of a reverse stock split in a 1-for-10 ratio. The reverse stock split was approved by the Company’s shareholders at a special meeting held on March 17, 2010 and by its Board of Directors. The Company’s ticker symbol will revert to CADM in approximately 20 business days. American Stock Transfer and Trust Company, LLC, will act as the exchange agent, and can be contacted at (877) 248-6417 or (718) 921-8317.

About Cardima

Cardima, Inc. has developed the PATHFINDER® Series of diagnostic catheters, and the NAVIPORT® deflectable guiding catheter, the INTELLITEMP® Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.

PATHFINDER®, NAVIPORT®, REVELATION®, INTELLITEMP®, VUEPORT® and NAVIPORT® are registered trademarks of Cardima, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.

Company Contact Cardima, Inc. Richard Gaston, M.D. 510-354-0300 http://www.Cardima.com or Investor Contacts Lippert/Heilshorn & Associates Jody Cain 310-691-7100 jcain@lhai.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES